Phase I ISIS-APOARx single and multiple dose study in volunteers.

Trial Profile

Phase I ISIS-APOARx single and multiple dose study in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs ISIS APOARx (Primary)
  • Indications Atherosclerosis
  • Focus Adverse reactions
  • Sponsors Isis Pharmaceuticals
  • Most Recent Events

    • 03 Sep 2015 Trial identifier 2012-004909-27 is no longer appearing in the European Clinical Trials Database.
    • 24 Jul 2015 Results published online in the Lancet.
    • 22 Jul 2015 Results published in an Isis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top